Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy

Cancer
Samuel BralGuy Storme

Abstract

The objective of the current study was to evaluate the feasibility and toxicity of radiation dose escalation with concurrent chemotherapy using helical tomotherapy (HT) in patients with inoperable, locally advanced, stage III nonsmall cell lung cancer (LANSCLC) (grading determined according to the American Joint Committee on Cancer 6th edition grading system). This phase 1/2 study was designed to determine the maximum tolerated dose (MTD) of radiotherapy in patients with LANSCLC administered concurrently with docetaxel and cisplatin. Radiotherapy was delivered using HT. A dose per fraction escalation was applied starting at 2 grays (Gy), with an increase of 6% per dose cohort (DC). The Radiation Therapy Oncology Group acute radiation morbidity score was used to monitor pulmonary, esophageal, and cardiac toxicity. Dose escalation was performed in 34 patients over 5 DCs to a dose per fraction of 2.48 Gy. No differences were observed in acute toxicity between the different DCs. However, a significant increase in late lung toxicity in DC IV, which received a fraction size of 2.36 Gy, necessitated a halt in further dose escalation with the MTD defined as 2.24 Gy per fraction. The overall incidence of acute grade > or =3 esophageal a...Continue Reading

References

Apr 1, 1995·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
Jun 1, 1997·Chest·C F Mountain, C M Dresler
Sep 25, 1998·International Journal of Radiation Oncology, Biology, Physics·S L KwaR K Ten Haken
Sep 16, 1999·International Journal of Radiation Oncology, Biology, Physics·M V GrahamC A Perez
Oct 26, 1999·Physics in Medicine and Biology·K J RuchalaT R Mackie
Feb 13, 2001·International Journal of Radiation Oncology, Biology, Physics·M MehtaJ Fowler
Apr 16, 2003·International Journal of Radiation Oncology, Biology, Physics·Ramesh GopalGeorge Starkschall
Sep 27, 2003·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Jochen WillnerMichael Flentje
Mar 6, 2004·International Journal of Radiation Oncology, Biology, Physics·Hasan MurshedJoe Y Change
Mar 6, 2004·International Journal of Radiation Oncology, Biology, Physics·H Helen LiuRadhe Mohan
Apr 27, 2004·The British Journal of Radiology·A W Beavis
Sep 15, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Petr ZatloukalLadislav Pecen
Sep 28, 2004·Physics in Medicine and Biology·Tomas KronJake Van Dyk
Oct 30, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark A SocinskiJulian G Rosenman
Feb 25, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giannicola D'AddarioFrances A Shepherd
Jul 2, 2005·International Journal of Radiation Oncology, Biology, Physics·Dirk De RuysscherPhilippe Lambin
Jul 21, 2005·International Journal of Radiation Oncology, Biology, Physics·Katja M LangenPatrick A Kupelian
Aug 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pierre FournelUNKNOWN Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie
Feb 28, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A AupérinUNKNOWN Meta-Analysis of Cisplatin/carboplatin based Concomitant Chemotherapy in non-small cell Lung Cancer (MAC3-LC) Group
May 2, 2006·International Journal of Radiation Oncology, Biology, Physics·Feng-Ming KongRandall K Ten Haken
Jun 23, 2006·Physics in Medicine and Biology·T R Mackie
Aug 15, 2006·International Journal of Radiation Oncology, Biology, Physics·Jose S A BelderbosJoos V Lebesque
Jul 20, 2007·Physics in Medicine and Biology·Curtis WoodfordJake Van Dyk
Mar 18, 2008·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Sonal SuraKenneth E Rosenzweig
Apr 29, 2008·International Journal of Radiation Oncology, Biology, Physics·Vladimir A SemenenkoX Allen Li
May 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark A SocinskiEverett E Vokes
Aug 12, 2008·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Giovanni Mauro CattaneoRiccardo Calandrino

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.